Global SPECT and PET Radiopharmaceuticals Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global SPECT and PET Radiopharmaceuticals Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
SPECT and PET Radiopharmaceuticals report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global SPECT and PET Radiopharmaceuticals market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2029. Demand from Hospitals and Clinics are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for SPECT and PET Radiopharmaceuticals industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029.
Globally, SPECT and PET Radiopharmaceuticals key companies include GE Healthcare, Cardinal Health, Curium Pharma, China Isotope & Radiation, Jubilant Life Sciences, Bracco, Yantai Dongcheng Pharmaceutical, Lantheus Medical Imaging, Inc. and Eczacıbaşı Monrol Nuclear Products, etc. GE Healthcare, Cardinal Health, Curium Pharma are top 3 players and held % share in total in 2022.
SPECT and PET Radiopharmaceuticals can be divided into Single Photon Emission Computed Tomography (SPECT) Radiopharmaceuticals and Positron Emission Tomography (PET) Radiopharmaceuticals, etc. Single Photon Emission Computed Tomography (SPECT) Radiopharmaceuticals is the mainstream product in the market, accounting for % share globally in 2022.
SPECT and PET Radiopharmaceuticals is widely used in various fields, such as Hospitals, Clinics and Others,, etc. Hospitals provides greatest supports to the SPECT and PET Radiopharmaceuticals industry development. In 2022, global % share of SPECT and PET Radiopharmaceuticals went into Hospitals filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global SPECT and PET Radiopharmaceuticals market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report

GE Healthcare
Cardinal Health
Curium Pharma
China Isotope & Radiation
Jubilant Life Sciences
Bracco
Yantai Dongcheng Pharmaceutical
Lantheus Medical Imaging, Inc.
Eczacıbaşı Monrol Nuclear Products
Novartis International AG
Siemens
Segment by Type
Single Photon Emission Computed Tomography (SPECT) Radiopharmaceuticals
Positron Emission Tomography (PET) Radiopharmaceuticals
Hospitals
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the SPECT and PET Radiopharmaceuticals market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2029).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, SPECT and PET Radiopharmaceuticals introduction, etc. SPECT and PET Radiopharmaceuticals Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of SPECT and PET Radiopharmaceuticals market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
North America, Europe and Asia Pacific are the key regions for SPECT and PET Radiopharmaceuticals industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029.
Globally, SPECT and PET Radiopharmaceuticals key companies include GE Healthcare, Cardinal Health, Curium Pharma, China Isotope & Radiation, Jubilant Life Sciences, Bracco, Yantai Dongcheng Pharmaceutical, Lantheus Medical Imaging, Inc. and Eczacıbaşı Monrol Nuclear Products, etc. GE Healthcare, Cardinal Health, Curium Pharma are top 3 players and held % share in total in 2022.
SPECT and PET Radiopharmaceuticals can be divided into Single Photon Emission Computed Tomography (SPECT) Radiopharmaceuticals and Positron Emission Tomography (PET) Radiopharmaceuticals, etc. Single Photon Emission Computed Tomography (SPECT) Radiopharmaceuticals is the mainstream product in the market, accounting for % share globally in 2022.
SPECT and PET Radiopharmaceuticals is widely used in various fields, such as Hospitals, Clinics and Others,, etc. Hospitals provides greatest supports to the SPECT and PET Radiopharmaceuticals industry development. In 2022, global % share of SPECT and PET Radiopharmaceuticals went into Hospitals filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global SPECT and PET Radiopharmaceuticals market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report

By Company
GE Healthcare
Cardinal Health
Curium Pharma
China Isotope & Radiation
Jubilant Life Sciences
Bracco
Yantai Dongcheng Pharmaceutical
Lantheus Medical Imaging, Inc.
Eczacıbaşı Monrol Nuclear Products
Novartis International AG
Siemens
Segment by Type
Single Photon Emission Computed Tomography (SPECT) Radiopharmaceuticals
Positron Emission Tomography (PET) Radiopharmaceuticals
Segment by Application
Hospitals
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the SPECT and PET Radiopharmaceuticals market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2029).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, SPECT and PET Radiopharmaceuticals introduction, etc. SPECT and PET Radiopharmaceuticals Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of SPECT and PET Radiopharmaceuticals market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
